Matricelf Ltd (MTLF) - Net Assets
Based on the latest financial reports, Matricelf Ltd (MTLF) has net assets worth ILA8.29K ILA (≈ $22.24 USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA10.99K ≈ $29.47 USD) and total liabilities (ILA2.70K ≈ $7.23 USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Matricelf Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA8.29K |
| % of Total Assets | 75.47% |
| Annual Growth Rate | 33.14% |
| 5-Year Change | 442.25% |
| 10-Year Change | N/A |
| Growth Volatility | 341.7 |
Matricelf Ltd - Net Assets Trend (2019–2024)
This chart illustrates how Matricelf Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Matricelf Ltd balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Matricelf Ltd (2019–2024)
The table below shows the annual net assets of Matricelf Ltd from 2019 to 2024. For live valuation and market cap data, see Matricelf Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ILA15.17 Million ≈ $40.66K |
-43.42% |
| 2023-12-31 | ILA26.80 Million ≈ $71.86K |
-25.12% |
| 2022-12-31 | ILA35.79 Million ≈ $95.96K |
+36.46% |
| 2021-12-31 | ILA26.23 Million ≈ $70.32K |
+837.88% |
| 2020-12-31 | ILA2.80 Million ≈ $7.50K |
-22.80% |
| 2019-12-31 | ILA3.62 Million ≈ $9.71K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Matricelf Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6325528700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ILA162.00K | 1.07% |
| Other Components | ILA79.39 Million | 523.48% |
| Total Equity | ILA15.17 Million | 100.00% |
Matricelf Ltd Competitors by Market Cap
The table below lists competitors of Matricelf Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PODIUM MINERALS
F:55D
|
$23.72 Million |
|
System and Application Technologies Co. Ltd
KQ:060540
|
$23.73 Million |
|
ChemX Materials Ltd
AU:CMX
|
$23.74 Million |
|
Desane Group Holdings Ltd
AU:DGH
|
$23.74 Million |
|
Korea SE Corp
KQ:101670
|
$23.71 Million |
|
Hawthorn Resources Ltd
AU:HAW
|
$23.70 Million |
|
Seafresh Industry Public Company Limited
BK:CFRESH
|
$23.70 Million |
|
ProMIS Neurosciences Inc.
NASDAQ:PMN
|
$23.68 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Matricelf Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 26,804,000 to 15,166,000, a change of -11,638,000 (-43.4%).
- Net loss of 15,582 reduced equity.
- Other comprehensive income decreased equity by 27,293,000.
- Other factors increased equity by 15,670,582.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-15.58K | -0.1% |
| Other Comprehensive Income | ILA-27.29 Million | -179.96% |
| Other Changes | ILA15.67 Million | +103.33% |
| Total Change | ILA- | -43.42% |
Book Value vs Market Value Analysis
This analysis compares Matricelf Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.33x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1407.45x to 0.33x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | ILA0.21 | ILA302.50 | x |
| 2020-12-31 | ILA0.17 | ILA302.50 | x |
| 2021-12-31 | ILA3.01 | ILA302.50 | x |
| 2022-12-31 | ILA2.73 | ILA302.50 | x |
| 2023-12-31 | ILA1699.47 | ILA302.50 | x |
| 2024-12-31 | ILA923.97 | ILA302.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Matricelf Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.21x
- Recent ROE (-0.10%) is above the historical average (-47.07%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -31.24% | 0.00% | 0.00x | 1.16x | ILA-1.49 Million |
| 2020 | -153.82% | 0.00% | 0.00x | 2.12x | ILA-4.58 Million |
| 2021 | -62.30% | 0.00% | 0.00x | 1.10x | ILA-18.97 Million |
| 2022 | -34.88% | 0.00% | 0.00x | 1.10x | ILA-16.07 Million |
| 2023 | -0.05% | 0.00% | 0.00x | 1.13x | ILA-2.69 Million |
| 2024 | -0.10% | 0.00% | 0.00x | 1.21x | ILA-1.53 Million |
Industry Comparison
This section compares Matricelf Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $126,504,000
- Average return on equity (ROE) among peers: -40.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Matricelf Ltd (MTLF) | ILA8.29K | -31.24% | 0.33x | $23.72 Million |
| BioLine RX Ltd (BLRX) | $52.88 Million | -46.05% | 0.15x | $11.90 Million |
| BioLight Life Sciences Ltd (BOLT) | $8.03 Million | -214.92% | 2.08x | $6.79 Million |
| Bonus Biogroup (BONS) | $-6.38 Million | 0.00% | 0.00x | $129.32 Million |
| Can Fite Biopharma Ltd (CANF) | $-1.81 Million | 0.00% | 0.00x | $6.00 Million |
| Clal Biotechnology Industries Ltd (CBI) | $1.11 Billion | 7.88% | 0.13x | $14.21 Million |
| Compugen (CGEN) | $17.67 Million | -77.12% | 0.64x | $197.75 Million |
| DNA Biomed Solns (DNA) | $579.00K | 0.00% | 15.68x | $38.30 Million |
| Enlivex Therapeutics Ltd (ENLV) | $30.67 Million | -22.89% | 0.07x | $519.31K |
| Evogene (EVGN) | $63.42 Million | -48.01% | 0.20x | $5.42 Million |
| Kadimastem Ltd (KDST) | $-8.56 Million | 0.00% | 0.00x | $22.18 Million |
About Matricelf Ltd
Matricelf Ltd, a biotechnology company, develops a platform for autologous tissue engineering for various medical conditions. The company's regenerative medicine platform intends to cure a range of medical conditions, including spinal cord injuries, age-related macular degeneration, Parkinson's disease, and myocardial infarction, as well as for 3D bioprinting. Matricelf Ltd was incorporated in 20… Read more